Paliperidone Long-Acting Injections in Huntington’s Disease for Motor and Behavioural Disturbances
Oral antipsychotics are used to treat motor and behavioural disturbances in Huntington’s disease (HD). However, patients with behavioural disturbances are often non-compliant, thus the oral route is inappropriate. The effects of antipsychotic long-acting injections (LAI) in HD are significantly underrepresented in literature. Paliperidone LAI (P-LAI), an atypical antipsychotic, has benefits over other antipsychotics LAI with its long dosing interval and no initial oral overlap, but has no documented cases for this indication. This case of a 45-year-old female highlights the use of P-LAI for severe aggression and chorea secondary to HD causing failed placement in assisted-care accommodation and mobility via an electronic-wheelchair. Three weeks after commencing treatment, she could walk unassisted, and displayed no aggression. After 10 months, she still had significant improvements and resided in the same accommodation for 6 months without any concern. Thus, this case suggests that P-LAI may be a treatment option for non-compliant HD patients.
Compliance with Ethical Standards
The authors declare that no source of funding was obtained for this research.
Conflicts of interest
Dr Theo Theodoros has attended educational events organised by Jannsen: Pharmaceutical Companies of Johnson & Johnson (where expenses were paid). Nameer van Oosterom has not conflict of interest to declare.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was also approved by the Metro South Human Research Ethics Committee (reference number: HREC/18/QPAH/87).
A waiver of consent was granted for this project by the Metro South Human Research Ethics Committee.
- 5.Invega Sustenna. eMIMS. 2018. https://www.mimsonline.com.au/Search/Search.aspx.
- 7.Invega Trinza. eMIMS. 2018. https://www.mimsonline.com.au/Search/Search.aspx.
- 8.Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry. 2016;50(5):410–72. https://doi.org/10.1177/0004867416641195.CrossRefGoogle Scholar
- 9.Barnes TRE, Taylor DM, Young AH. The Maudsley prescribing guidelines in psychiatry. Newark: Wiley; 2018.Google Scholar